Dynavax falls on updated data for TLR9 agonist combo

Dynavax Technologies Corp. (NASDAQ:DVAX) lost $2.65 (14%) to $16.70 Thursday after reporting updated response data from the Phase Ib/II MEL-01 (KEYNOTE-184) trial evaluating

Read the full 239 word article

User Sign In